Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
Summary
Crinetics Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2025, with a net loss of $130.1 million, compared to a net loss of $76.8 million for the same period in 2024. The company launched PALSONIFY, its first FDA-approved treatment for acromegaly, which has seen positive uptake and reimbursement trends. Crinetics is advancing multiple clinical trials across its pipeline, with key milestones expected in the fourth quarter of 2025 and early 2026. The company expects cash, cash equivalents, and investments to fund its operations into 2029.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement